BASELINE CHARACTERISTICS FROM THE CARDIOVASCULAR OUTCOMES TRIAL OF OMECAMTIV MECARBIL, GALACTIC-HF (GLOBAL APPROACH TO LOWERING ADVERSE CARDIAC OUTCOMES THROUGH IMPROVING CONTRACTILITY IN HEART FAILURE)

Omecamtiv mecarbil (OM) is a novel, selective cardiac myosin activator that improves cardiac function, ventricular volumes, and NT-proBNP in patients with heart failure (HF) with reduced ejection fraction. GALACTIC-HF tests the hypotheses that OM can delay cardiovascular (CV) death, prevent HF